

PREGNANCY RELATED HEART DISEASES: A REVIEW

ABSTRACT:

To summarise the literature regarding susceptibility of pregnant women to heart disease, we have conducted a review using a PubMed search and other strategies during the month of february 2021. Studies were included if they reported information on heart disease in pregnant women pregnant existing conditions which can predispose the pregnant woman to cardiovascular disease included hypertension, diabetes mellitus, and congenital heart disease. Women often present with symptoms and signs of acute heart failure. On the other hand there is a disease which is directly related to pregnancy such as hypertension disorder of pregnancy and peripartum cardiomyopathy or where pregnancy increases risk of a disease as example, the risk of a myocardial infarction. This review summarises the knowledge about awareness on pregnancy related heart disease.

Keywords: pregnancy, awareness, heart disease, heart failure, Innovative technique, myocardial infarction.

INTRODUCTION:

Any disorder that affects the heart. Sometimes the term "heart disease" is used narrowly and incorrectly as a synonym for coronary artery disease. Heart disease is synonymous with cardiac disease but not with cardiovascular disease which is any disease of the heart or blood vessels(1)(2). Pregnancy is the term used to describe the period in which a fetus develops inside a woman's womb or uterus. Pregnancy usually lasts about 40 weeks, or just over 9 months, as measured from the last menstrual period to delivery. Health care providers refer to three segments of pregnancy, called trimesters (3). Heart failure is one of the most important complications in pregnant women with heart disease causing maternal and fetal mortality. Heart disease is the most common complication during pregnancy and occurs typically at the end of the second trimester. Heart disease of pregnancy encompasses a broad arena of pathologies (4). Heart disease may be an exacerbation of the existing conditions that the pregnant woman may already have or they may develop a new disease process that presents because of the complex hormonal changes and physiology of pregnancy. Ischemic heart disease in pregnant women is similar to the non pregnant woman. Risk factors which expose these individuals to ischemic heart disease include hypertension, hyperlipidemia, and hyperlipidemia, diabetes mellitus, obesity, smoking and immobility(5)(6). Many females enter pregnancy with heart disease. These individuals may be aware or unaware of these before pregnancy based on the level of function. The physiologic changes of pregnancy can prove challenging for these women to compensate (7,8).

The physiological changes of pregnancy (increases heart rate, increases circulating volume) are in full effect in the second trimester, these pregnancy patients may experience a severe exacerbation of their underlying heart disease. Besides angiotensin converting enzyme inhibitors and angiotensin receptors blockers, other medications used for heart disease can be resumed. Aortic stenosis in pregnancy is less common, it is often more challenging to treat. Beta blockers are not effective as they are mitral stenosis in reducing transvalvular gradient (9–11). Spontaneous coronary artery dissection is an atypical cause of acute myocardial infarction. Its incidence, however, increases in pregnant women. The aim of the study is to

raise awareness on pregnancy related heart disease. The literature review was carried out from scopus and the pubmed database from 2000 till date . Five steps process involved in selection of articles. They are identification of relevant articles, section of articles, data extraction and charting and final analysis and report. Recent similar, relevant publications are taken into account for the collection of knowledge and to get clear about it. Articles Collected through medline, embase Cochrane library.

CARDIOVASCULAR DISEASE IN PREGNANCY:

Cardiac diseases of pregnancy encompasses a broad arena of pathologies. There are many cardiac diseases during pregnancy but women are not aware and require further inquiry. Arrhythmia is the most common cardiac complication encountered during pregnancy in women with and without structural heart disease. Congestive heart disease has been an increase in the number of women of children bearing age with congestive heart disease and these women are not particularly at high risk for arrhythmias. (12). Blood pressure slightly decreases early in pregnancy, overall, more commonly diastolic blood pressure decreases and predominates over systolic blood pressure early in pregnancy. Usually, this value normalises or even increases by the end of pregnancy. Effects of maternal cardiac disease on pregnancy are preterm delivery, fetal growth restriction, fetal death and Congenital heart disease (13).

ASSESSMENT OF CARDIAC FUNCTION IN PREGNANCY:

The physiological change associated with pregnancy give rise to symptoms and signs which may cause confusion in the assessment of cardiac disorder such as dyspnoea, tachycardia, ankle oedema,softejection.The functional capacity or the functional reserve of the heart should be assessed because it is usually more important than the anatomical nature of the lesion. (14)(15)

ACUTE MYOCARDIAL INFARCTION IN PREGNANCY:

Acute myocardial infarction has been reported to occur with a frequency of 3 to 10 cases per 100000 deliveries. Pregnancy itself has not usually been thought of as a risk factor for acute myocardial infarction but pregnancy is accompanied by not only an increase in blood volume and altered thermodynamics but an increase in estrogen and progesterone. Oral estrogen and progestin at least have been implicated as a risk factor for cardiovascular disease.(16,17) The prevalence of certain cardiovascular risk factors, particularly advanced maternal age and obesity is increasing the incidence of pregnancy related acute myocardial infarction may also be increasing,but there has been insufficient data to evaluate risk factors or trends. Because of the rarity of pregnancy related acute myocardial infarction,it is difficult to estimate it's incidence, identify it's risk factors and report outcomes such as mortality.(18)(19)

CONGESTIVE HEART DISEASE:

The risks associated with pregnancy in women with congenital heart disease include adverse maternal and fetal outcomes. Pregnancy results in sufficient hemodynamic changes that may not be well tolerated in women with congenital heart disease. Cardiac output, heart rate and blood volume all increase substantially with pregnancy (20). Systemic vascular resistance decreases during pregnancy but will increase dramatically at the time of delivery. Delivery also results in a sudden increase in venous return. Determining which women are at increased risk of adverse outcomes and providing advice about pregnancy is optimally done before conception as a part of a full cardiac evaluation(21)(12).

PULMONARY STENOSIS:

Pulmonary stenosis is a condition characterized by obstruction to blood flow from the right ventricle to the pulmonary artery. This obstruction is caused by narrowing at one or more points from the pulmonary artery. Areas of potential narrowing include thickened muscle below the pulmonary valves, stenosis of the valve itself or stenosis of the pulmonary artery above the valve (22)(23).

The most common form of pulmonary stenosis is obstruction at the valve itself referred to as pulmonary valve stenosis. Those with mild or moderate pulmonary stenosis can often tolerate pregnancy, those with more severe pulmonary stenosis may experience heart complications during pregnancy. They should have the obstruction repaired before becoming pregnant once, as most women do well in pregnancy. Puerperal cardiomyopathy, myocardial infarction, aortic dissection, cardiomyopathy and myocarditis, primary pulmonary hypertension, endocarditis, CFC, dysrhythmia can cause maternal deaths in pregnant women.(24) Our team has extensive knowledge and research experience that has translate into high quality publications (25).(26–39) ,(40–44)

CONCLUSION:

This study will provide a cornerstone to promote further studies and to motivate people during pregnancy. Complicated heart disease was found as important risk factors for intrauterine growth restriction among pregnant mothers suffering from heart disease. Stress is a major component of cardiac events. It may not cause disease , but it can trigger heart attacks. Every Woman should be aware about heart disease during pregnancy.

REFERENCES

1. Hossin MZ, Falkstedt D, Allebeck P, Mishra G, Koupil I. Early life programming of adult ischemic heart disease within and across generations: The role of the socioeconomic context. *Soc Sci Med.* 2021 Mar 4;275:113811.
2. Braunwald's Heart Disease Family of Books [Internet]. Heart Failure: a Companion to Braunwald's Heart Disease. 2020. p. xix – xx. Available from: <http://dx.doi.org/10.1016/b978-0-323-60987-6.09001-3>
3. Gerrard M. Antecedents of Pregnancy and Pregnancy Attrition in First Term Women Marines [Internet]. 1989. Available from: <http://dx.doi.org/10.21236/ada216868>
4. Child JS, Perloff JK, Koos B. Management of Pregnancy and Contraception in Congenital Heart Disease [Internet]. *Congenital Heart Disease in Adults.* 2009. p. 194–220. Available from: <http://dx.doi.org/10.1016/b978-1-4160-5894-6.50013-7>
5. S S, Sapna S, Asha PS. PREDICTORS OF PREGNANCY RELATED COMPLICATIONS IN WOMEN WITH HEART DISEASE [Internet]. Vol. 7, *Journal of Evolution of Medical and Dental Sciences.* 2018. p. 1228–31. Available from: <http://dx.doi.org/10.14260/jemds/2018/280>
6. Kovacs AH, Harrison JL, Colman JM, Sermer M, Siu SC, Silversides CK. Pregnancy and Contraception in Congenital Heart Disease: What Women Are Not Told [Internet]. Vol. 52, *Journal of the American College of Cardiology.* 2008. p. 577–8. Available from: <http://dx.doi.org/10.1016/j.jacc.2008.05.013>

7. Clark SM, Dunn HE, Hankins GDV. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. *Semin Perinatol*. 2015 Nov;39(7):548–55.
8. Hannah R, Ramani P, Brundha MP, Sherlin HJ, Ranjith G, Ramasubramanian A, et al. Liquid Paraffin as a Rehydrant for Air Dried Buccal Smear. *Research Journal of Pharmacy and Technology*. 2019;12(3):1197–200.
9. Autore C, Conte MR, Piccininno M. Risk associated with pregnancy in hypertrophic cardiomyopathy [Internet]. Vol. 12, *ACC Current Journal Review*. 2003. p. 101. Available from: [http://dx.doi.org/10.1016/s1062-1458\(03\)00100-4](http://dx.doi.org/10.1016/s1062-1458(03)00100-4)
10. Harsha L, Brundha MP. Prevalence of Dental Developmental Anomalies among Men and Women and its Psychological Effect in a Given Population. *Journal of Pharmaceutical Sciences and Research; Cuddalore*. 2017 Jun 20;9(6):869–73.
11. Timothy CN, Samyuktha PS, Brundha MP. Dental pulp Stem Cells in Regenerative Medicine--A Literature Review. *Research Journal of Pharmacy and Technology*. 2019;12(8):4052–6.
12. Walker F. Cardiac disease in pregnancy [Internet]. *OSH Cardiac Anaesthesia*. 2010. p. 563–71. Available from: <http://dx.doi.org/10.1093/med/9780199209101.003.35>
13. Kafka H, Chung NAY. Impact of pregnancy on long-term outcomes in women with heart disease. *Heart Disease and Pregnancy*. 2011;227–33.
14. Roos-Hesselink JW, Johnson MR. *Pregnancy and Congenital Heart Disease*. Springer; 2017. 280 p.
15. Elkayam U, Goland S, Pieper PG, Silversides CK. High-Risk Cardiac Disease in Pregnancy: Part II. *J Am Coll Cardiol*. 2016 Aug 2;68(5):502–16.
16. Lawes R. Acute myocardial infarction in pregnancy [Internet]. Vol. 40, *Nursing*. 2010. p. 72. Available from: <http://dx.doi.org/10.1097/01.nurse.0000387756.60605.71>
17. Preethikaa S, Brundha MP. Awareness of diabetes mellitus among general population. *Research Journal of Pharmacy and Technology*. 2018;11(5):1825–9.
18. Furenäs E, Eriksson P, Wennerholm U-B, Dellborg M. Cardiac Complications during Pregnancy Related to Parity in Women with Congenital Heart Disease. *Cardiology*. 2020 Jul 13;145(8):533–42.
19. Hameed AB, Sklansky MS. Pregnancy: Maternal and Fetal Heart Disease [Internet]. Vol. 32, *Current Problems in Cardiology*. 2007. p. 419–94. Available from: <http://dx.doi.org/10.1016/j.cpcardiol.2007.04.004>
20. Bhatla N, Lal S, Behera G, Kriplani A, Mittal S, Agarwal N, et al. Cardiac disease in pregnancy. *Int J Gynaecol Obstet*. 2003 Aug;82(2):153–9.
21. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: A systematic review [Internet]. Vol. 10, *Journal of Clinical Lipidology*. 2016. p. 1081–90. Available from: <http://dx.doi.org/10.1016/j.jacl.2016.07.002>

22. Kafka H, Babu-Narayan SV, Li W. Cardiac monitoring during pregnancy [Internet]. *Heart Disease and Pregnancy*. p. 43–52. Available from: <http://dx.doi.org/10.1017/cbo9781316156063.008>
23. Shafuddin E, Chang C, Hancox R. Cardiac function during COPD exacerbations assessed by cardiac MRI [Internet]. *Monitoring airway disease*. 2019. Available from: <http://dx.doi.org/10.1183/13993003.congress-2019.oa1919>
24. Avila WS, Rossi EG, Ramires JAF, Grinberg M, Bortolotto MRL, Zugaib M, et al. Pregnancy in patients with heart disease: experience with 1,000 cases. *Clin Cardiol*. 2003 Mar;26(3):135–42.
25. Anita R, Paramasivam A, Priyadharsini JV, Chitra S. The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients. *Am J Cancer Res*. 2020 Aug 1;10(8):2546–54.
26. Jayaseelan VP, Paramasivam A. Emerging role of NET inhibitors in cardiovascular diseases. *Hypertens Res*. 2020 Dec;43(12):1459–61.
27. Sivakumar S, SmilineGirija AS, VijayashreePriyadharsini J. Evaluation of the inhibitory effect of caffeic acid and gallic acid on tetR and tetM efflux pumps mediating tetracycline resistance in *Streptococcus* sp., using computational approach. *Journal of King Saud University - Science*. 2020 Jan 1;32(1):904–9.
28. SmilineGirija AS. Delineating the Immuno-Dominant Antigenic Vaccine Peptides Against gacS-Sensor Kinase in *Acinetobacter baumannii*: An in silico Investigational Approach. *Front Microbiol*. 2020 Sep 8;11:2078.
29. IswaryaJaisankar A, SmilineGirija AS, Gunasekaran S, VijayashreePriyadharsini J. Molecular characterisation of csgA gene among ESBL strains of *A. baumannii* and targeting with essential oil compounds from *Azadirachta indica*. *Journal of King Saud University - Science*. 2020 Dec 1;32(8):3380–7.
30. Girija ASS. Fox3+ CD25+ CD4+ T-regulatory cells may transform the nCoV's final destiny to CNS! *J Med Virol* [Internet]. 2020 Sep 3; Available from: <http://dx.doi.org/10.1002/jmv.26482>
31. Jayaseelan VP, Ramesh A, Arumugam P. Breast cancer and DDT: putative interactions, associated gene alterations, and molecular pathways. *Environ Sci Pollut Res Int*. 2021 Jun;28(21):27162–73.
32. Arumugam P, George R, Jayaseelan VP. Aberrations of m6A regulators are associated with tumorigenesis and metastasis in head and neck squamous cell carcinoma. *Arch Oral Biol*. 2021 Feb;122:105030.
33. Kumar SP, Girija ASS, Priyadharsini JV. Targeting NM23-H1-mediated inhibition of tumour metastasis in viral hepatitis with bioactive compounds from *Ganoderma lucidum*: A computational study. *pharmaceutical-sciences* [Internet]. 2020;82(2). Available from: <https://www.ijpsonline.com/articles/targeting-nm23h1-mediated-inhibition-of-tumour-metastasis-in-viral-hepatitis-with-bioactive-compounds-from-ganoderma-lucidum-a-comp-3883.html>

34. Girija SA, Priyadharsini JV, Paramasivam A. Prevalence of carbapenem-hydrolyzing OXA-type β -lactamases among *Acinetobacter baumannii* in patients with severe urinary tract infection. *Acta Microbiol Immunol Hung*. 2019 Dec 9;67(1):49–55.
35. Priyadharsini JV, Paramasivam A. RNA editors: key regulators of viral response in cancer patients. *Epigenomics*. 2021 Feb;13(3):165–7.
36. Mathivadani V, Smiline AS, Priyadharsini JV. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA-1) with Murrayakoengii bio-compounds: An in-silico approach. *Acta Virol*. 2020;64(1):93–9.
37. Girija As S, Priyadharsini J V, A P. Prevalence of Acb and non-Acb complex in elderly population with urinary tract infection (UTI). *Acta Clin Belg*. 2021 Apr;76(2):106–12.
38. Anchana SR, Girija SAS, Gunasekaran S, Priyadharsini VJ. Detection of csgA gene in carbapenem-resistant *Acinetobacter baumannii* strains and targeting with *Ocimum sanctum* biocompounds. *Iran J Basic Med Sci*. 2021 May;24(5):690–8.
39. Girija ASS, Shoba G, Priyadharsini JV. Accessing the T-Cell and B-Cell Immuno-Dominant Peptides from *A.baumannii* Biofilm Associated Protein (bap) as Vaccine Candidates: A Computational Approach. *Int J Pept Res Ther*. 2021 Mar 1;27(1):37–45.
40. Arvind P TR, Jain RK. Skeletally anchored forsus fatigue resistant device for correction of Class II malocclusions-A systematic review and meta-analysis. *OrthodCraniofac Res*. 2021 Feb;24(1):52–61.
41. Venugopal A, Vaid N, Bowman SJ. Outstanding, yet redundant? After all, you may be another *Cholutedca* Bridge! *Semin Orthod*. 2021 Mar 1;27(1):53–6.
42. Ramadurai N, Gurunathan D, Samuel AV, Subramanian E, Rodrigues SJL. Effectiveness of 2% Articaine as an anesthetic agent in children: randomized controlled trial. *Clin Oral Investig*. 2019 Sep;23(9):3543–50.
43. Varghese SS, Ramesh A, Veeraiyan DN. Blended Module-Based Teaching in Biostatistics and Research Methodology: A Retrospective Study with Postgraduate Dental Students. *J Dent Educ*. 2019 Apr;83(4):445–50.
44. Mathew MG, Samuel SR, Soni AJ, Roopa KB. Evaluation of adhesion of *Streptococcus mutans*, plaque accumulation on zirconia and stainless steel crowns, and surrounding gingival inflammation in primary molars: randomized controlled trial [Internet]. Vol. 24, *Clinical Oral Investigations*. 2020. p. 3275–80. Available from: <http://dx.doi.org/10.1007/s00784-020-03204-9>